Excellent posts regarding NP interview with Dr. Be
Post# of 148177
(Total Views: 714)
Posted On: 07/05/2020 7:09:36 PM
Excellent posts regarding NP interview with Dr. Been.
As pretty much everything has been discussed I just wanted to say what where my main takeaways (running the risk of appearing repetitive):
1) I liked the interview from the personal side. Either NP deserves a Oscar of the academy or he is a down-to-earth, authentic, compassionate person. This for me is important. I don't care if the communication si not always clear (as he communicates frequently) but I care if it is truthful.
2) So now we are aiming at listing in NASDAQ and not NYSE-Market (AMEX). This was news to me.
3) NP is banking on FDA approving Leronlimab on the basis of a "unmet medical need", and, as far as I am concerned, this is exactly what it is, unless, of course the 9 GILD members on the COVID board decide that Remdesivir is meeting all the COVID needs of the people and there is no need for more drugs.
Being a bit sarcastic here but the unmet medical need will be a powerful factor when FDA decides whether it will approve Leronlimab after a (very successful) P2 trial or not.
4) Dr. Patterson is indeed analyzing the samples (or at least some). However, I noticed a little reticence of NP to let it be know that we where completely dependent on analysis from IncellRx. I took this as an indication that this might be taken the wrong way as Dr. Patterson has been very outspoken in supporting CYDY in several interviews. This explains why he has gone silent in the last weeks while analyzing the trial blood samples (from which he must have a good idea of what to expect.)
5) NP said forcefully that the interim "peek" will have more patients. This mean that we need to be patient as the results will be delayed: if we had 51 more a month ago and he wants to "do 100" (as example) we will need to wait 28 more days (at least) from the enrollment of patient 100.
6) Oncology data is still very good (CTC count is zero). This is humongous and, probably, much more important that the whole COVID indication. This has been under the radar for some time but its importance will come to bear once the pandemic is gone.
7) Three more papers coming. This is very good and supportive. Would like to hear what is happening with Dr. Patterson's one.
As pretty much everything has been discussed I just wanted to say what where my main takeaways (running the risk of appearing repetitive):
1) I liked the interview from the personal side. Either NP deserves a Oscar of the academy or he is a down-to-earth, authentic, compassionate person. This for me is important. I don't care if the communication si not always clear (as he communicates frequently) but I care if it is truthful.
2) So now we are aiming at listing in NASDAQ and not NYSE-Market (AMEX). This was news to me.
3) NP is banking on FDA approving Leronlimab on the basis of a "unmet medical need", and, as far as I am concerned, this is exactly what it is, unless, of course the 9 GILD members on the COVID board decide that Remdesivir is meeting all the COVID needs of the people and there is no need for more drugs.
Being a bit sarcastic here but the unmet medical need will be a powerful factor when FDA decides whether it will approve Leronlimab after a (very successful) P2 trial or not.
4) Dr. Patterson is indeed analyzing the samples (or at least some). However, I noticed a little reticence of NP to let it be know that we where completely dependent on analysis from IncellRx. I took this as an indication that this might be taken the wrong way as Dr. Patterson has been very outspoken in supporting CYDY in several interviews. This explains why he has gone silent in the last weeks while analyzing the trial blood samples (from which he must have a good idea of what to expect.)
5) NP said forcefully that the interim "peek" will have more patients. This mean that we need to be patient as the results will be delayed: if we had 51 more a month ago and he wants to "do 100" (as example) we will need to wait 28 more days (at least) from the enrollment of patient 100.
6) Oncology data is still very good (CTC count is zero). This is humongous and, probably, much more important that the whole COVID indication. This has been under the radar for some time but its importance will come to bear once the pandemic is gone.
7) Three more papers coming. This is very good and supportive. Would like to hear what is happening with Dr. Patterson's one.
(13)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼